Physiological and Pharmacological Roles of FGF21 in Cardiovascular Diseases

Cardiovascular disease (CVD) is one of the most severe diseases in clinics. Fibroblast growth factor 21 (FGF21) is regarded as an important metabolic regulator playing a therapeutic role in diabetes and its complications. The heart is a key target as well as a source of FGF21 which is involved in he...

Full description

Bibliographic Details
Main Authors:	Cheng, Peng, Zhang, Fangfang, Yu, Lechu, Lin, Xiufei, He, Luqing, Li, Xiaokun, Lu, Xuemian, Yan, Xiaoqing, Tan, Yi, Zhang, Chi
Format:	Online
Language:	English
Published:	Hindawi Publishing Corporation 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876232/

id	pubmed-4876232
recordtype	oai_dc
spelling	pubmed-48762322016-05-31 Physiological and Pharmacological Roles of FGF21 in Cardiovascular Diseases Cheng, Peng Zhang, Fangfang Yu, Lechu Lin, Xiufei He, Luqing Li, Xiaokun Lu, Xuemian Yan, Xiaoqing Tan, Yi Zhang, Chi Review Article Cardiovascular disease (CVD) is one of the most severe diseases in clinics. Fibroblast growth factor 21 (FGF21) is regarded as an important metabolic regulator playing a therapeutic role in diabetes and its complications. The heart is a key target as well as a source of FGF21 which is involved in heart development and also induces beneficial effects in CVDs. Our review is to clarify the roles of FGF21 in CVDs. Strong evidence showed that the development of CVDs including atherosclerosis, coronary heart disease, myocardial ischemia, cardiac hypertrophy, and diabetic cardiomyopathy is associated with serum FGF21 levels increase which was regarded as a compensatory response to induced cardiac protection. Furthermore, administration of FGF21 suppressed the above CVDs. Mechanistic studies revealed that FGF21 induced cardiac protection likely by preventing cardiac lipotoxicity and the associated oxidative stress, inflammation, and apoptosis. Normally, FGF21 induced therapeutic effects against CVDs via activation of the above kinases-mediated pathways by directly binding to the FGF receptors of the heart in the presence of β-klotho. However, recently, growing evidence showed that FGF21 induced beneficial effects on peripheral organs through an indirect way mediated by adiponectin. Therefore whether adiponectin is also involved in FGF21-induced cardiac protection still needs further investigation. Hindawi Publishing Corporation 2016 2016-05-09 /pmc/articles/PMC4876232/ /pubmed/27247947 http://dx.doi.org/10.1155/2016/1540267 Text en Copyright © 2016 Peng Cheng et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Cheng, Peng Zhang, Fangfang Yu, Lechu Lin, Xiufei He, Luqing Li, Xiaokun Lu, Xuemian Yan, Xiaoqing Tan, Yi Zhang, Chi
spellingShingle	Cheng, Peng Zhang, Fangfang Yu, Lechu Lin, Xiufei He, Luqing Li, Xiaokun Lu, Xuemian Yan, Xiaoqing Tan, Yi Zhang, Chi Physiological and Pharmacological Roles of FGF21 in Cardiovascular Diseases
author_facet	Cheng, Peng Zhang, Fangfang Yu, Lechu Lin, Xiufei He, Luqing Li, Xiaokun Lu, Xuemian Yan, Xiaoqing Tan, Yi Zhang, Chi
author_sort	Cheng, Peng
title	Physiological and Pharmacological Roles of FGF21 in Cardiovascular Diseases
title_short	Physiological and Pharmacological Roles of FGF21 in Cardiovascular Diseases
title_full	Physiological and Pharmacological Roles of FGF21 in Cardiovascular Diseases
title_fullStr	Physiological and Pharmacological Roles of FGF21 in Cardiovascular Diseases
title_full_unstemmed	Physiological and Pharmacological Roles of FGF21 in Cardiovascular Diseases
title_sort	physiological and pharmacological roles of fgf21 in cardiovascular diseases
description	Cardiovascular disease (CVD) is one of the most severe diseases in clinics. Fibroblast growth factor 21 (FGF21) is regarded as an important metabolic regulator playing a therapeutic role in diabetes and its complications. The heart is a key target as well as a source of FGF21 which is involved in heart development and also induces beneficial effects in CVDs. Our review is to clarify the roles of FGF21 in CVDs. Strong evidence showed that the development of CVDs including atherosclerosis, coronary heart disease, myocardial ischemia, cardiac hypertrophy, and diabetic cardiomyopathy is associated with serum FGF21 levels increase which was regarded as a compensatory response to induced cardiac protection. Furthermore, administration of FGF21 suppressed the above CVDs. Mechanistic studies revealed that FGF21 induced cardiac protection likely by preventing cardiac lipotoxicity and the associated oxidative stress, inflammation, and apoptosis. Normally, FGF21 induced therapeutic effects against CVDs via activation of the above kinases-mediated pathways by directly binding to the FGF receptors of the heart in the presence of β-klotho. However, recently, growing evidence showed that FGF21 induced beneficial effects on peripheral organs through an indirect way mediated by adiponectin. Therefore whether adiponectin is also involved in FGF21-induced cardiac protection still needs further investigation.
publisher	Hindawi Publishing Corporation
publishDate	2016
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876232/
_version_	1613582618472742912

Physiological and Pharmacological Roles of FGF21 in Cardiovascular Diseases

Similar Items